Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -9.09% as of the fiscal period ended Friday, July 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-9.09%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 583 covered companies
CURRENT VS SECTOR MEDIAN
+77.02%
vs the sector median at left
MiniMed Group, Inc. Common Stock
Market Cap
$5.54B
Return on Equity (ROE)
-9.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.37B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.78B
Return on Equity (ROE)
12.33%
TTM Avg
0.28%
3Y Avg
12.51%
5Y Avg
-14.51%
Market Cap
$5.29B
Return on Equity (ROE)
-25.83%
TTM Avg
-24.61%
3Y Avg
-23.01%
5Y Avg
-16.21%
Market Cap
$5.28B
Return on Equity (ROE)
-70.85%
TTM Avg
-75.76%
3Y Avg
-70.25%
5Y Avg
-57.77%
Market Cap
$5.86B
Return on Equity (ROE)
-21.80%
TTM Avg
-16.70%
3Y Avg
-22.00%
5Y Avg
-23.98%
Market Cap
$5.23B
Return on Equity (ROE)
-161.00%
TTM Avg
-110.38%
3Y Avg
-86.51%
5Y Avg
-75.97%
Market Cap
$5.95B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$5.15B
Return on Equity (ROE)
-79.37%
TTM Avg
-38.23%
3Y Avg
-43.73%
5Y Avg
-49.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. Common Stock (MMED) | $5.54B | -9.09% | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.37B | 18.24% | 20.62% | 17.32% | 27.02% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.78B | 12.33% | 0.28% | 12.51% | -14.51% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.29B | -25.83% | -24.61% | -23.01% | -16.21% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.28B | -70.85% | -75.76% | -70.25% | -57.77% |
| CG Oncology Inc. (CGON)vs › | $5.86B | -21.80% | -16.70% | -22.00% | -23.98% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.23B | -161.00% | -110.38% | -86.51% | -75.97% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | -39.33% | -54.18% | -65.89% | -59.69% |
| Erasca, Inc. (ERAS)vs › | $5.15B | -79.37% | -38.23% | -43.73% | -49.41% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.99B | 20.38% | 5.87% | 3.40% | 3.36% |
ROE
-9.1%
ROA
-7.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -9.09% |
